Last reviewed · How we verify
GRISACTIN ULTRA (GRISEOFULVIN, ULTRAMICROCRYSTALLINE)
GRISACTIN ULTRA (generic name: GRISEOFULVIN, ULTRAMICROCRYSTALLINE) is a drug developed by WYETH AYERST. It is currently FDA-approved for Onychomycosis due to dermatophyte, Tinea barbae, Tinea capitis.
At a glance
| Generic name | GRISEOFULVIN, ULTRAMICROCRYSTALLINE |
|---|---|
| Sponsor | WYETH AYERST |
| Target | Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
- Onychomycosis due to dermatophyte
- Tinea barbae
- Tinea capitis
- Tinea corporis
- Tinea cruris
- Tinea pedis
Common side effects
Key clinical trials
- A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin (Phase 1)
- A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Femal (Phase 1)
- Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis (Phase 3)
- Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis (Phase 3)
- An Open Label, Randomized, Balanced, Three Treatment, Three Period, Three Sequence, Single Dose, Crossover Study to Evaluate the Bioequivalence of Test Griseofulvin Tablets, 500 mg Versus Reference Gr (Phase 1)
- A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Femal (Phase 1)
- A Randomized, Double-Blinded, Placebo-Controlled Study Observing the Efficacy of Selenium Sulfide 1% Shampoo, Ketoconazole 2% Shampoo, and Ciclopirox 1% Shampoo as Adjunctive Treatments for Tinea Capi (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GRISACTIN ULTRA CI brief — competitive landscape report
- GRISACTIN ULTRA updates RSS · CI watch RSS
- WYETH AYERST portfolio CI
Frequently asked questions about GRISACTIN ULTRA
What is GRISACTIN ULTRA?
GRISACTIN ULTRA (GRISEOFULVIN, ULTRAMICROCRYSTALLINE) is a pharmaceutical drug developed by WYETH AYERST, indicated for Onychomycosis due to dermatophyte, Tinea barbae, Tinea capitis.
What is GRISACTIN ULTRA used for?
GRISACTIN ULTRA is indicated for Onychomycosis due to dermatophyte, Tinea barbae, Tinea capitis, Tinea corporis, Tinea cruris.
Who makes GRISACTIN ULTRA?
GRISACTIN ULTRA is developed and marketed by WYETH AYERST (see full WYETH AYERST pipeline at /company/wyeth-ayerst).
What is the generic name of GRISACTIN ULTRA?
GRISEOFULVIN, ULTRAMICROCRYSTALLINE is the generic (nonproprietary) name of GRISACTIN ULTRA.
What development phase is GRISACTIN ULTRA in?
GRISACTIN ULTRA is FDA-approved (marketed).
What does GRISACTIN ULTRA target?
GRISACTIN ULTRA targets Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin.
Related
- Target: All drugs targeting Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin
- Manufacturer: WYETH AYERST — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Onychomycosis due to dermatophyte
- Indication: Drugs for Tinea barbae
- Indication: Drugs for Tinea capitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing